Theraclion S.A (ALTHE) | Stock Overview & Key Data
Theraclion S.A. | Small-cap | Healthcare
Theraclion S.A. | Small-cap | Healthcare
Theraclion S.A Performance Comparison
Stock Range
Today's Range
Low: €0.67
High: €0.73
on August 22, 2025
52 Week Range
Low: €0.14
High: €0.80
on March 14, 2025
on July 25, 2025
All-Time High: €13.35 on May 5, 2014
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€31.4M
EPS
-0.10
P/E Ratio (TTM)
-5.58
Forward P/E
6.58
P/B Ratio
N/A
PEG Ratio
6.58
Div. Yield
N/A
ROE
-203.90%
Beta
-0.154
Debt to Equity
-66,510.16
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-294.95%
Profit Margin
-346.01%
Returns and Earnings
Return on Assets (TTM)
-28.29%
Return on Equity (TTM)
-203.90%
EBITDA
€-6.5M
Net Income (TTM)
€-5.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.02
Quarterly Revenue Growth (YoY)
27.00%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Theraclion S.A ALTHE | 31.40M Small-cap | 9.23% | 86.84% | 153.57% | 273.68% | 97.22% | 136.67% | -36.61% | -44.09% |
| Guerbet S.A GBT | 293.77M Mid-cap | -1.34% | 2.80% | 9.70% | -18.03% | -17.72% | -34.38% | 12.16% | -25.38% |
| Eurobio Scientific ALERS | 251.86M Mid-cap | -0.39% | 1.00% | 0.00% | -0.39% | 0.00% | 2.43% | 32.11% | 120.00% |
| Median Technologies ALMDT | 91.70M Small-cap | -12.31% | 14.08% | 5.38% | -10.31% | -44.58% | -66.28% | -77.83% | -63.62% |
| Affluent Medical AFME | 60.00M Small-cap | 14.58% | 32.00% | 18.71% | 23.13% | 18.71% | -15.38% | -42.71% | -79.25% |
| Novacyt S.A ALNOV | 34.83M Small-cap | -2.04% | 2.13% | 2.13% | -18.64% | -21.31% | -58.97% | -57.14% | -85.88% |
Ownership & Short Interest
Insider Ownership
62.15%
Institutional Ownership
1.33%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
164K
Average 90-Day Volume
153K
Theraclion S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Theraclion S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALTHE's 52-week high and low?
- In the last 52 weeks, Theraclion S.A reached a high of €0.80 (on July 25, 2025) and a low of €0.14 (on March 14, 2025).
- What is the market cap and P/E ratio for ALTHE?
- Curious about Theraclion S.A's size and valuation? Its market capitalization stands at 31.40M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.58, and the forward P/E (looking ahead) is 6.58.
- Does ALTHE pay dividends? If so, what's the yield?
- As for dividends, Theraclion S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Theraclion S.A's main competitors or similar companies to consider before investing?
When looking at Theraclion S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Guerbet S.A
GBT293.77M Healthcare Medical Devices -34.38% 12.16% Eurobio Scientific
ALERS251.86M Healthcare Medical Devices 2.43% 32.11% Median Technologies
ALMDT91.70M Healthcare Medical Devices -66.28% -77.83% Affluent Medical
AFME60.00M Healthcare Medical Devices -15.38% -42.71% Novacyt S.A
ALNOV34.83M Healthcare Medical Devices -58.97% -57.14% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Theraclion S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Theraclion S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -203.90%, the Debt to Equity ratio from the most recent quarter is -66,510.16, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ALTHE?
- Looking at Theraclion S.A's growth, its revenue over the trailing twelve months (TTM) was €830K. Compared to the same quarter last year (YoY), quarterly revenue grew by 27.00%, and quarterly earnings saw a YoY growth of N/A.
- How much of ALTHE stock is held by insiders and institutions?
- Wondering who owns Theraclion S.A stock? Company insiders (like executives and directors) hold about 62.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 1.33%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.